The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The partnership is a significant step in delivering advanced cancer therapies to patients.
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Subscribe To Our Newsletter & Stay Updated
